PARIS — A vaccine jointly developed by Pfizer and BioNTech is 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announces.
Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” Pfizer chairman and CEO Albert Bourla says in a statement.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most,” Bourla adds.
Across much of the globe, COVID-19 infections rates are soaring to record highs, with hospital intensive care units filling up and death tolls mounting as well.
Based on supply projections, the companies say they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021.
— AFP
We can't do this work alone.
The war with Iran has been draining for all of us in Israel. But when I heard about a high casualty incident – ballistic missile impacts in Arad and Dimona that left nearly 200 people wounded – I drank a cup of coffee, packed a bag, and headed south.
There, I spoke with Shilgit, the head of an after-school program for underprivileged youth. Standing outside her destroyed center, Shilgit said it was a miracle that no children were hurt and spoke about the community coming together in the hours since.
As a Times of Israel reporter, I’m committed to telling stories of resilience like Shilgit’s. But my colleagues and I can't do this alone. If you value work like this, please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to keep real human reporting like this going.
— Stav Levaton, military reporter
Yes, I'll join
Yes, I'll join
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
From the Liveblog of
Monday, November 9, 2020
